BLACK WEEKSFlakonai −15% · rinkiniai −10% · kita −5%su koduNemokamas siuntimas Vokietijoje nuo €200

Šis puslapis išverstas automatiškai ir jame gali būti klaidų. Ar lietuvių kalba yra jūsų gimtoji? Mielai sulauksime jūsų atsiliepimų ir pataisymų.Siųsti atsiliepimą

The Peptide Desk The Peptide Desk
RAD-140 (Testolone), produkto nuotrauka
SARMs

RAD-140 (Testolone)

SARMs

  • Siunčiame iš Vokietijos

Užsakymas

Vieneto kaina - Nemokamas siuntimas Vokietijoje nuo 200 € Black Weeks metu
  • DHL su sekimu
  • Diskreti pakuotė

4.6 iš 5 TrustpilotAtsiliepimų: 73

Taip pat ieškoma kaip: Testolon

Trumpai

RAD-140 (Testolone) skaičiais

Pagrindiniai rodikliai iš mūsų žinyno. Vilkite tašką kreive, kad pamatytumėte, kiek lieka po vienos dozės, pagal skaičiavimą.

Visas žinyno įrašas

How long does it stay in the body?

Share left after one dose, calculated with a half-life of ~1.9 days

Half-life ~1.9 days
After 3.7 days: 25 %
Day 1, next dose69 %Day 1.949 %Day 3.725 %Day 5.612.4 %Day 9.33.1 %

Simplified model without an absorption phase, half-life from the TPD lexicon.

Half-life

44.7hours

measured in humans

Class
SARMnon-steroidal
Use
Oraldaily
Sizes
10 mg1 size in the shop

Produktui RAD-140 (Testolone) laboratorinės analizės dar nėra. Balsuoti už taiUžsakykite tyrimą, mes apmokame pusęVisos laboratorinės analizės

Žinios

Viskas apie RAD-140 (Testolone)

FAQ

Dažnai užduodami klausimai

Šaltiniai kiekvienam atsakymui: žinyno įrašas

Dar turite klausimų?

Parašykite mums, mūsų komanda jums padės.

How does RAD-140 work?

According to ChEMBL RAD-140 binds to the androgen receptor with a Ki of 7 nM and activated it in muscle cells in the lab. Yu and colleagues found that it activates the receptor in breast cancer cells but not in prostate cancer cells. That is the tissue preference SARMs aim for.

Is RAD-140 approved?

No. On ClinicalTrials.gov there is a single study for RAD140, the completed phase 1 study in breast cancer (as of 26 October 2026). There are no studies in healthy people. Everything here is the state of research, not a recommendation.

What did the phase 1 study show?

22 heavily pretreated women with breast cancer took RAD-140 daily. SHBG fell in all 18 women measured, PSA rose in 16 of 20, a sign of action at the receptor. After 24 weeks 18.2 percent had a benefit, one woman a partial response. Liver values rose often.

What about the liver?

In the phase 1 study AST rose in 59.1 percent, ALT in 45.5 percent. In addition there are case reports. A 26-year-old had acute liver injury, his values normalised two months after stopping. A 24-year-old developed cholestatic liver injury after five weeks of use.

Are there reports on the heart?

Yes, as a case report: Padappayil and colleagues describe a young man with possible acute myocarditis after self-use of RAD-140 for bodybuilding. A case report does not prove a link, but it shows what to watch for.

Is muscle gain proven in humans?

No. The first description by Miller and colleagues shows anabolic effects in animal models. In humans there is only the phase 1 study in women with breast cancer, which did not measure muscle mass.

Palyginimai

Kuo skiriasi

Susiję

Susiję produktai